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Overexpression of the wild-type SPT1 subunit lowers
Desoxysphingolipid levels and rescues the phenotype of HSAN1
Abstract
Mutations in the SPTLC1 subunit of serine palmitoyltransferase (SPT) cause an adult-onset, hereditary
sensory, and autonomic neuropathy type I (HSAN1). We previously reported that mice bearing a
transgene-expressing mutant SPTLC1 (tgSPTLC1(C133W)) show a reduction in SPT activity and
hyperpathia at 10 months of age. Now analyzed at a later age, we find these mice develop sensory loss
with a distal small fiber neuropathy and peripheral myelinopathy. This phenotype is largely reversed
when these mice are crossed with transgenic mice overexpressing wild-type SPTLC1 showing that the
mutant SPTLC1 protein is not inherently toxic. Simple loss of SPT activity also cannot account for the
HSAN1 phenotype, since heterozygous SPTLC1 knock-out mice have reduced SPT activity but are
otherwise normal. Rather, the presence of two newly identified, potentially deleterious deoxysphingoid
bases in the tgSPTLC1(C133W), but not in the wild-type, double-transgenic tgSPTLC1(WT + C133W)
or SPTLC1(+/-) mice, suggests that the HSAN1 mutations alter amino acid selectivity of the SPT
enzyme such that palmitate is condensed with alanine and glycine, in addition to serine. This
observation is consistent with the hypothesis that HSAN1 is the result of a gain-of-function mutation in
SPTLC1 that leads to accumulation of a toxic metabolite.
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Mutations in the SPTLC1 subunit of serine palmitoyltransferase (SPT) cause an adult-onset, hereditary sensory, and autonomic neurop-
athy type I (HSAN1). We previously reported that mice bearing a transgene-expressingmutant SPTLC1 (tgSPTLC1C133W) show a reduc-
tion in SPT activity and hyperpathia at 10months of age. Now analyzed at a later age, we find thesemice develop sensory losswith a distal
small fiber neuropathy and peripheral myelinopathy. This phenotype is largely reversed when these mice are crossed with transgenic
mice overexpressing wild-type SPTLC1 showing that the mutant SPTLC1 protein is not inherently toxic. Simple loss of SPT activity also
cannot account for the HSAN1 phenotype, since heterozygous SPTLC1 knock-out mice have reduced SPT activity but are otherwise
normal. Rather, the presence of two newly identified, potentially deleterious deoxysphingoid bases in the tgSPTLC1C133W, but not in the
wild-type, double-transgenic tgSPTLC1WT C133WorSPTLC1/mice, suggests that theHSAN1mutations alter aminoacid selectivity of
the SPT enzyme such that palmitate is condensed with alanine and glycine, in addition to serine. This observation is consistent with the
hypothesis that HSAN1 is the result of a gain-of-function mutation in SPTLC1 that leads to accumulation of a toxic metabolite.
Introduction
Hereditary sensory neuropathies are rare disorders characterized
by progressive sensory loss predominantly affecting the lower
limbs (Auer-Grumbach et al., 2003; Nicholson, 2006). Sensory
loss is often preceded by hyperpathia and spontaneous shooting
or lancinating pain. As the disease progresses, sensory loss can
give rise to ulcers, mutilation of the fingers and toes, and skin and
bone infections. Linkage analysis has identified genetic loci re-
sponsible for several autosomal dominant inherited neuropa-
thies (Nicholson, 2006). One of these, hereditary sensory and
autonomic neuropathy type I (HSAN1), is caused by missense
mutations in the SPTLC1 gene encoding a subunit of the enzyme
serine palmitoyltransferase (SPT) (Bejaoui et al., 2001;Nicholson
et al., 2001).
To date, three SPTLC1mutations, C133W, C133Y, and V144D,
havebeenconclusively linked toHSAN1.Eachmutation reduces the
in vitro activity of the enzyme, as measured by the incorporation of
labeled serine with SPT. Despite the impaired in vitro activity of the
enzyme, lymphoblastsofHSAN1patients shownoalteration in total
sphingolipid levels (Dedov et al., 2004). Similarly, transgenic
SPTLC1C133W mice demonstrate a 60% reduction in SPT activity
but no significant change in total ceramide levels. By 10 months of
age, they develop hyperpathia andmotor deficits, peripheralmyelin
thinning, loss of visceral innervation, and indications of neuronal
stress within the dorsal root ganglia (McCampbell et al., 2005).
To determine the basis by which mutations in SPTLC1
result in HSAN1, transgenic mice overexpressing wild-type
(WT) and C133W SPTLC1 were generated and examined for
SPT activity and neurological phenotypes. In addition, WT
and C133W transgenic mice were crossed and F1 double-
mutant progeny examined to distinguish between the possi-
bility that the C133W mutant protein is inherently toxic or
that reduced SPT activity is responsible for the disease. This
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latter possibility was also examined by generating heterozygous
SPTLC1 knock-out mice.
Materials andMethods
Transgene construction and generation of transgenic mice have previ-
ously been described (McCampbell et al., 2005). The final transgene
construct consisted of the chicken betaactin promoter with cytomega-
lovirus immediate early gene-enhancer elements, followed by the
SPTLC1 cDNA with hemagglutinin (HA), and the rabbit -globin poly-
adenylation signal. Mice were generated with
standard techniques in the BL6/C3H back-
ground. Presence of the transgene was detected
by PCR amplification of genomic DNA ex-
tracted with the DNeasy Tissue Extraction kit
(Qiagen). Multiplex PCR was completed with
primers for the transgene (F, 5CGAAAAAC-
CATCCTGCTCTC-3; R, 5GGACAGACGG
TTC CAG TGTT-3) and an endogenous lo-
cus, the ABCD1 gene (F, 5-GAGGGAGGTGG
AAGGAAAGA-3; R, 5GAAGG GTTGTT-
GCTCTGACC-3). We performed Western
blots for protein levels and measured SPT en-
zyme activity (brain and liver) in microsomal
preparations (McCampbell et al., 2005). Due
to the high similarity between hamster SPTLC1
mRNAs and mouse SPTLC1 mRNA (89%
identical) and the existence of KpnI site in both
mRNAs at the same location, cutting with
KpnI was unable to distinguish PCR products
of the hamster transgenes from endogenous
mouse SPTLC1 expression. Therefore, a sec-
ond digestion of the PCR products with PstI
was conducted to distinguish the hamster
mRNA frommouse mRNA (PstI exists only in
hamster, not in mouse SPTLC1 mRNA). Het-
erozygous SPT knock-out animals were cre-
ated with the SPTLC1 knock-out cell line
AD0062 obtained from the Sanger Institute
Gene trap resource. The cell line was knocked
down by insertion of a  geo cassette within
intron 2 of the target gene and genotyping of
the mice performed by RT-PCR for the gene
trap vector.
Behavioral and sensory assays. Motor func-
tion was assessed by rotorod analysis in an ac-
celerating rod paradigm.Mice were acclimated
to the rotorod apparatus for 3 d. For use in the
trial, a mouse was required to remain on a
steadily rotating rod for 1 min for three times.
Eachmouse was given five trials a day for 3 d to
successfully meet the criteria. Eight mice per
group successfully completed the trial. Latency
to fall was measured as the rod speed was in-
creased from 5 to 40 r.p.m. over 5 min. Each
mouse was tested in three trials per day over
3 d. The mean latencies to fall were compared
on each day by a one-way ANOVA. Mice were
tested at 12months and 14months of age. Sen-
sory performance was assessed as previously
described (Broomet al., 2004).Mechanical and
cold allodynia, as well as mechanical and ther-
mal hyperalgesia, were examined. Mice were
tested at 12 months and 14 months of age. Dif-
ferences were tested by Mann–Whitney (Von
Frey and Pin Prick) or ANOVA (acetone and
hot plate tests).
Histology and electron microscopy.Mice at 15
months of age were anesthetized, followed by
transcardial perfusion with 0.9% saline and
then with Bouin’s solution. Whole mouse was postfixed for 2 weeks at
4°C in Bouin’s solution. Paraffin embedded sections were cut at 4 mm
and stained with hematoxylin and eosin, Luxol fast blue or silver stain.
For analysis of sciatic nerve, dorsal root ganglion and spinal cord separate
transcardial perfusions with dissections were undertaken. Immunohis-
tochemistry was performed on paraffin-embedded (5 m), free-floating
(35m), and frozen (20m) sections.We used commercially antibodies
(iba-1, CD 68, myelin basic protein, glial fibrillary protein). Some anti-
bodies needed high temperature antigen retrieval, such as steaming in 10
Figure 1. Overexpression of the wild-type SPT1 subunit rescues the phenotype of HSAN1mice. Western blots of transgene (A)
as well as endogenous SPTLC1 (B) expression in liver (L), brain (B), and pancreatic tissue (P) inWT, wild-type SPTLC1 overexpress-
ing (TGWT),mutant SPTLC1 C133W (TG C133W) anddTGmice (arrowspoint to anticipatedmolecularweight of SPTLC1). AnHA tagwas
introduced to facilitate identification of the transgene. C, Western blots of liver and brain SPTLC1 in heterozygote knock-out mice
(/) andwild-type (/) animals.D, In the liver, brain, and spinal cord of thedouble-transgenicmice, the level ofWTSPTLC1
transcript is twice ashighas those for themutant SPTLC1 transgene.E, SPTactivity inbrain tissueof transgenic andknock-outmice:
SPT of SPTLC1 C133Wmice (TG C133W) is inhibited but restored in dTG. In brain, SPT is decreased by 25% in heterozygous knock-out
mice (/). SPTLC1 C133W mice (14-month-old) (TG C133W) were significantly slower to react in the hot plate test at 55°C ( p
0.05;F ) and less sensitive tomechanical stimuli (von Frey hair thresholds) ( p0.3;G). In the dTGanimals, statistically significant
improvements are seen.H, Rotorod performance is impaired in SPTLC1 C133Wmice (TG C133W)with a trend toward improvement in
the double transgenics. Sperm count inmice at 2months (I ) and 15months (J ). Themutant (TG C133W) animals have significantly
reduced sperm count compared with WT. This is restored in the dTG mice.
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mM citrate buffer, pH 6.0 or 20 mM Tris/0.65
mM EDTA/0.0005% Tween 20, pH 9.0. Nega-
tive controls with omission of the primary an-
tibodies were performed.
For the free-floating experiments, the tissue
was fixed in formalin, washed in two changes of
0.4 M Sorensen’s phosphate buffer for 72 h,
protected in 20% glycerol overnight, then fro-
zen and cut using a sliding microtome. The
sections were incubated with the primary anti-
bodies for 5 d at 4°C. Double-labeled sections
for light microscopy were pretreated as above
and incubated overnight at 4°C with two non-
cross-reacting primary antibodies (iba-1/
CD68, iba-1/MBP). Then first secondary
antibodies conjugated with alkaline phospha-
tase were applied. Fast Red was used as chromo-
gen (Roche Applied Sciences) before sections
were incubated with second secondary biotinyl-
ated antibodies. Sections were imaged using a
Leica DMR (Digital Module R) microscope and
an Optronix Magnafire digital camera. Whole
slides were scanned using an ArtixScan 4000tf
(Microtek) scanner and ScanWizardPro software.
Mice at 15months of age were perfused with
3% formaldehyde and 3% glutaraldehyde. The
distal sciatic nerves were dissected out and post-
fixed in 2.5% glutaraldehyde overnight. The
nerveswere osmificatedwith 1%osmiumtetrox-
ide and embedded in an Araldite resin. For axon
distribution, 10 random non-overlapping cross-
sectional regionswere imaged at 1900magnifi-
cation of three to four mice from each condition
[wild-type, wild-type SPTLC1 overexpressing,
mutant SPTLC1C133W, double-transgenic
(dTG), and heterozygote SPTLC1 knock-out
mice]. In Photoshop, tracings of axons andmye-
lin sheaths were filled to create a solid black area
representing the cross-sectional surface area of
myelin and axons. Using the particle analysis
function in ImageJ, the surface areas of axon and
myelin were computed. Axon diameter, total di-
ameterofmyelinatedaxon,myelin thickness, and
g-ratios (axon diameter/total axon and myelin
diameter) were calculated from surface areas.
Axon diameters grouped by size were plotted to
showrelative sizedistribution; the SD frommean
was calculated between animal averages. The to-
tal number of fibers was counted and fiber den-
sitycalculated.Statistical significancebetweenthe
four groups was determined by ANOVA.
Umyelinated fiber bundles were imaged at
25,000 magnification in 25 random non-
overlapping cross-sectional regions for two to
three mice from each condition (wild-type,
wild-type SPTLC1 overexpressing, mutant
SPTLC1C133W, double-transgenic, and hetero-
zygote SPTLC1 knock-out mice). The total
number of unmyelinated axons was counted
and axon diameters calculated as described
above. Unmyelinated axon diameters were
grouped by size and a relative size distribution for each condition plotted,
the SD frommeanwas calculated between animal averages, and statistical
significance between the four groups was determined by ANOVA.
Sperm analysis. Before transcardial perfusion, testes and epididymis
were removed and placed in phosphate buffer saline. The caudal epidid-
ymis was separated for sperm analysis. Both testes from each animal were
separated and weighted in an electronic balance and fixed with Bouin’s
solution. The sperm suspension was prepared by mincing the caudal
epididymis in 1 ml human tubal fluid with 10% FBS. For analysis, the
sperm suspension was in culture for 1 h at 5% CO2 in an air incubator.
Sperm count was analyzed in aMakler chamber.Motility was assessed by
counting the number of motile sperm with forward progression, motile
sperm without forward progression, and nonmotile sperm. Fixed testes
were embedded in paraffin and stained with hematoxyline and eosin for
histology. Statistical significance was calculated with Student’s t test.
Lipid analysis. Lipid content was analyzed in plasma, brain, spinal
cord, sciatic nerve, and testes. The tissue was cut into small pieces and
Figure 2. Mutant SPTLC1 C133Wmice (TG C133W) have smaller axons andmyelin abnormalities in the distal sciatic nerve.A, Low-
and high-power electron microscopic images show cross-sections of the distal sciatic nerves. Frequent indentures are seen in the
myelin sheathsof themutant SPLTC1mice (arrowhead)but absent in all other groups; Scalebars: 10and5m.B, Histogramof the
distribution of axon diameter of the distal sciatic nerve in 15-month-old WT, wild-type overexpressing (TGWT), SPTLC1 C133W
(TG C133W), and dTG mice. Myelinated axons in the SPTLC1 C133W mice appear smaller than in wild-type animals (TG C133W mean
axon diameter of 2.64mvsWTmean of 3.16m; p 0.05; see open arrow). There is a dropout of small unmyelinated axons in
themutant (TG C133W) animals0.2m (see closed arrow in B and EM images in C; scale bar, 50 nm) and a significant reduction
in total unmyelinated axons by35% [p 0.05; D; number of unmyelinated axons in 25 field-of-view (25,000)]. These
findings are reversed in the dTG animals. The g-ratios of mutant (TG C133W) versus WT versus wild-type SPTLC1 (TGWT) overex-
pressing animals (E) and dTG versus mutant (TG C133W) (F ) are plotted relative to the axon diameter with the best fit, linear
regression indicated for each of themice.Myelin thinning occurs in distal sciatic axons ofmutant SPTLC1 C133Wmice and is restored
in double-transgenic mice.
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homogenized in ice-cold HET buffer (50 mMHEPES pH 8, 1 mM EDTA,
0.2% TX100) using a Potter–Elvehjem glass homogenizer. The protein
concentration of the homogenate was determined using a Bradford re-
agent (BioRad). The lipids of an homogenate equivalent to 80g protein
were extracted and subjected to acid and base hydrolysis as described
previously (Riley et al., 1999). Extracted lipids were solubilized in 56.7%
methanol/33.3% ethanol/10% water and derivatized with ortho-phthal-
dialdehyd (OPA). The lipids were separated on a C18 column and the OPA
derivates analyzed by a serial arrangement of a fluorescence detector
(HP1046A;HewlettPackard)followedbyamassspectrometrydetector(LCMS-
2010A; Shimadzu). The liquid chromatography (LC) system consisted of an
LC-10Ai solvent deliverymodule (Shimadzu), SIL-10ADvp automatic injector
(Shimadzu). Chromatographic conditions were
AmmAcetate (5mM):MetOH (17:83) for 25min
followed by a 5 min wash step with 100% Me-
tOH at a flowrate of 300 l/min. Atmospheric
pressure chemical ionization was used for ion-
ization. Non-natural C17 sphingosine (Avanti
Polar Lipids) was used as internal standard.
Results
As previously reported, mice transgenic
for either theWT or the mutant (C133W)
alleles of SPTLC1 (tgSPTLC1WT and
tgSPTLC1C133W) showed high expression
of the transgenes in liver, pancreas, and
brain (Fig. 1A) that significantly exceed
endogenous SPTLC1 levels (Fig. 1B)
(McCampbell et al., 2005).More importantly,
brain microsomal SPT activity was reduced
60% in the tgSPTLC1C133W mice but
was unaltered in the tgSPTLC1WT mice,
an observation suggesting that SPT activ-
ity is limited by SPTLC2 (Fig. 1E). Only
heterodimers of SPTLC1/2 are func-
tional, and an excess in SPTLC1 alone is
not able to make functional homodimers
(Hanada, 2003).
Aging mutant SPTLC1C133Wmice
(TGC133W) develop a small
fiber neuropathy
Initial characterizationof the tgSPTLC1C133W
mice showed evidence of hyperpathia at
10 months of age (McCampbell et al.,
2005). In the present study, we find that
when tested at 12 months of age, these
mice are no longer hyperpathic (data not
shown), and by 14 months, they become
hypopathic, in conjunction with the de-
velopment of a small fiber sensory neu-
ropathy. The functional sensory deficits at
14months are evident in bothmechanical
sensitivity ( p 0.05) and hotplate testing
( p 0.04) relative to wild-typemice (Fig.
1F,G). Moreover, at 14 months, the ani-
mals also showed deficits in motor func-
tion as gauged by rotorod testing (Fig.
1H). While there was a decreased latency
to fall on rotarod testing in the wild-type
SPTLC1 overexpressing transgenic mice
as well, they showed no abnormalities on
sensory testing or axon number or size of
myelinated and unmyelinated fibers. As
McCampbell et al. (2005) previously re-
ported a slight increase in hindlimb activity at 10 months of age,
we speculate whether coordination difficulties may contribute to
the poor motor performance of these mice.
When killed at 15 months, electron microscopy of sciatic
nerves in the tgSPTLCC133W mice revealed a loss of small unmy-
elinated axons (0.2 m in diameter) (Fig. 2A– D). Myelinated
axons showed smaller diameters and abnormal Schwann cells
consistent with degeneration of the distal sciatic nerve (Fig.
2B,E). This supports the finding of amixedmotor-sensory, large
and small fiber neuropathy. Themyelin itself showed the unusual
Figure 3. Distal sciatic nerves of mutant SPTLC1 C133Wmice (TG C133W) reveal amononuclear phagocytic cell reaction. A, Sciatic
nerves of TG C133W show more TNF- staining compared with the wild-type mice. This is associated with the presence of CD68-
positive macrophages; scale bar, 50m. B, The boxed area of mutant sciatic nerve is magnified; scale bar, 20m. C, Ultrastruc-
tural analysis reveals lipid droplets within macrophages in the TG C133W mutant; scale bar, 0.25 m. D, Dorsal root ganglion
neurons at L3 are surrounded by abundant TNF- in the mutant TG C133W mice.
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feature of numerous indentures on cross-sectional view, and
nearby lipid-laden macrophages were prominent (Fig. 3). Sciatic
nerves of TGC133W also showed more TNF- staining associated
with the presence of CD68 positive macrophages compared with
the wild-type mice. Reactive microglia, as identified by iba1-
positive staining, were also foundwithin the dorsal column of the
spinal cord (data not shown).
In addition to the neurologic abnormalities, we noted poor
fertility in the mutant tgSPTLC1C133W mice and poor sperm
count as early as 2 months of age, which persisted up until 15
months of age (Fig. 1 I, J). Sperm motility was reduced by 40%
and testes weight by 30% in the mutant compared with the wild-
type mice at 2 months of age. Interestingly, at 15 months, the
wild-type SPTLC1 overexpressing mice had twice the sperm
count compared with the wild type. These findings are consistent
with the fact that SPTLC1 is a negative regulator of ABCA1
(Tamehiro et al., 2008) and that ABCA1 overexpressing mice
have aspermatogenesis (Selva et al., 2004).
Overexpression of the wild-type SPT1 subunit rescues the
phenotype of HSAN1 mice
All the abnormal phenotypes seen in the tgSPTLC1C133W mice
were corrected to variable degrees in the dTG mice (Fig. 1). In
addition, as seen in Figure 1A, mice overexpressingWT SPTLC1
have higher transgene expression than do the mice overexpress-
ing C133W SPTLC1.We found that in the dTGmice, the level of
WT SPTLC1 transcript is twice as high as those for the C133W
SPTLC1 transgene (Fig. 1D). This is consistent with our interpre-
tation that preponderance of SPTLC1–SPLTC2 heterodimers are
formed with the WT SPTLC1 transgene and not the C133W
SPTLC1 transgene, thus contributing to normalization of SPT
activity (Fig. 1E). While this result eliminates the possibility that
the mutant protein is inherently toxic, it does not prove that
simple loss of SPT activity accounts for the HSAN1 pathology.
To directly address whether decreased SPT activity is respon-
sible for the HSAN1 phenotype, the heterozygous knock-out
mice were analyzed. Despite the fact that SPTLC1 protein expres-
sion (Fig. 1C) and SPT activity (Fig. 1E) were decreased, het-
erozygous knock-out mice showed no evidence of neuropathy as
gauged by testing of temperature sensitivity, mechanical sensitiv-
ity, and rotorod at 14 months (data not shown). To ensure that
there was no delayed phenotype evolving, we assessed the mice
until 22 months of age. Like the dTG mice, detailed behavioral
and morphological studies revealed no evidence of a neuropathy
(supplemental Fig. 1, available at www.jneurosci.org as supple-
mental material), and no fertility problems were seen in the het-
erozygous knock-out mice.
Accumulation of deoxysphingoid bases in C133Wmutant
transgenic mice
These findings strongly suggest that simple haploinsufficiency can-
not explain the HSAN1 phenotype and suggest that the pathogenic
mechanism is more complex. In this context, the finding that the
deoxysphingoid bases (DSB) are elevated in humans with C133W
mutations is of particular interest (Hornemann et al., 2008). We,
therefore, investigated whether these novel deoxysphingoid bases
were present in the mutant tgSPTLC1C133W mice. Strikingly, these
compounds were significantly elevated in plasma, sciatic nerve, and
testes of the tgSPTLC1C133Wmice as compared withWTmice (Fig.
4). In contrast, unaffected compartments of the nervous system,
such as brain and spinal cord, showed little or no accumulation of
desoxysphingoidbases.Thus, thepresenceofdesoxysphingoidbases
corresponds to the pattern of pathology. Furthermore, the levels of
these compounds were also much lower in the dTG mice. This is
entirely consistentwith the preponderance ofWTheterodimers and
the lack of a sufficient number of mutant heterodimers to generate
toxic levels of these deoxysphingoid bases in the dTGmice.No atyp-
ical sphingolipids were detected in heterozygous knock-out mice.
Discussion
Hereditary sensory and autonomic neuropathy type I (HSAN1) is
the most frequent type of hereditary neuropathy that primarily
affects sensory neurons (Nicholson, 2006). It is caused bymutations
within the SPTLC1 subunit of SPT which catalyzes the pyridoxal
5-phosphate (PLP)-dependentcondensationof L-serineandpalmi-
toyl–coenzyme A, the first and rate-limiting step in the synthesis of
sphingolipids (Hanada et al., 1997). We previously reported that
transgenic mice expressing the mutant SPTLC1C133W develop hy-
Figure 4. Accumulation of deoxysphingoid bases in C133W mutant transgenic mice. Total
lipids from WT, wild-type overexpressing (TGWT), heterozygote knock-out (/),
SPTLC1 C133Wmice (TG C133W), and dTGwere extracted and subjected to an acid and base hydro-
lyzes.A, All C133Wmutants showplasma levels form18:0 bases in excess of 200pmol/ml ( p
0.05, by t test). SomedTGmice havemild accumulation ofm18:0 but not beyond this threshold.
Levels of m18:0 are 100 pmol/ml in the other conditions. In all mice, levels of 18:0 are
dramatically higher than m18:1. B, Similar to humans with the C133Wmutation (Hornemann
et al., 2008) m17:0 is present in plasma of SPTLC1 C133W mutant mice but not other animals.
However, levels of m17:1 are not detectable (n.d.). C, D, In SPTLC1 C133W mutant mice, high
levels ofm17:0 are present in the sciatic nerve and lower levels in brain, testes, spinal cord, and
liver. Similar to plasma, double-transgenic mice have mild accumulation of m18:0 in sciatic
nerve but much reduced compared with the C133Wmutant mice.
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perpathia and motor deficits, peripheral myelin thinning, and the
loss of visceral innervation at the age of 10months (McCampbell et
al., 2005). Here, we report, in follow-up analysis, that thesemice are
no longer hyperpathic at the age of 12 months and at the age of 14
months, manifest a small fiber sensory neuropathy and deficits in
sensory andmotor function similar toHSAN1patients. SPT activity
is60% reduced in these animals.
An unexpected finding in our study was the presence of
mononuclear phagocytic cells in both distal sciatic nerve and
spinal cord of SPTLC1C133W mutant mice. Phagocytosis facili-
tates Wallerian degeneration of axotomized fibers distal to a
nerve lesion and activation of spinal microglia dominates the
early glial response in the CNS to peripheral nerve injury (Scholz
andWoolf, 2007). The reactivemicroglial response along sensory
nerve pathways, as well as the concurrent proliferation of astro-
cytes, supports the view that there is selective vulnerability caused
by the C133Wmutation.
Furthermore, we observe poor fertility, a significantly lower
sperm count, impaired spermmobility, and lower testis weight in
the transgenic SPTLC1C133W animals. All these impairments
were absent in double-transgenic mice that overexpress both the
SPTLC1 wild-type and SPTLC1C133W subunits. These double-
transgenic mice have normal SPT activity, no evidence of neu-
ropathy and normal fertility. In addition, heterozygous SPTLC1
knock-out animals, with reduced SPT activity, also show no evi-
dence of neuropathy. Thus, our results exclude the possibility
that the C133W mutation creates an inherently toxic protein, as
has been reported in other neurodegenerative diseases such as
Alzheimer’s and Parkinson’s disease (Lowe et al., 1988; Mayer et
al., 1989). They also eliminate a simple haploinsufficiency as the
basis of the disease. Indeed, Hojjati et al. (2005) observed no
neurological phenotype with even greater reductions in SPT
(M. R. Hojjati, personal communication), and normal individu-
als have SPT activities that are lower than those in some HSAN1
patients (Dedov et al., 2004). Finally, heterozygous knock-out
SPTLC2 mice that also had a 50% reduction in SPT activity were
neurologically intact.
The finding that mice and patients expressing the C133W
mutant SPTLC1 protein make two unusual DSB provides an at-
tractive alternative hypothesis for the molecular basis of HSAN1.
We propose that the HSAN1 mutations in SPTLC1 alter the ac-
tive site of the heterodimer to allow themutant SPT to use alanine
and glycine as alternative substrates, leading to the generation of
1-deoxy-sphinganine (m18:0) and 1-deoxymethyl-sphinganine
(m17:0), respectively. This is consistent with recent homology
modeling for the C133W mutant showing a steric clash between
W133 and the backbone carbonyl oxygen of the active site lysine
residue in SPTLC2 that covalently binds the PLP cofactor (Yard
et al., 2007). The PLP cofactor forms the Schiff base with serine,
and thus, alterations associatedwith theHSAN1mutations could
easily alter substrate selectivity of the enzyme. Thus, although it
has yet to be proven, it is conceivable that perturbation of geom-
etry of the active site accounts for these changes.
A consequence of the missing C1–OH group in the DSB is the
inability of these metabolites to form either complex sphingolip-
ids or to undergo the phosphorylation necessary for degradation.
Interestingly, the macrophages identified in peripheral nerve of
the mutant mice show prominent lipid droplets (Fig. 3); our
analysis reveals that the lipids may at least in part represent se-
questered DSB or degenerative myelin products (Fig. 4).
In conclusion, our results provide no evidence that either sim-
ple haploinsufficency or an inherent toxicity of the SPTLC1 mu-
tant proteins underlies the pathology of HSAN1. Rather, based
on the identification of potentially toxic long-chain bases inmice
expressing the mutant protein, we propose that disease-causing
mutations result in altered substrate selectivity leading to the
accumulation of toxic metabolites. That HSAN1 apparently re-
flects the acquisition of novel activity of SPT provides an expla-
nation for the very specific mutations that result in this rare
disease.
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